Crispr Therapeutics [CRSP] vs Bio-Techne [TECH] Detailed Comparison

TLDR: Quick Comparison Summary

Based on 13 vital metrics comparison: Crispr Therapeutics wins in 6 metrics, Bio-Techne wins in 5 metrics, with 0 ties. Crispr Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crispr Therapeutics Bio-Techne Better
P/E Ratio (TTM) -10.50 60.87 Crispr Therapeutics
Price-to-Book Ratio 2.15 3.92 Crispr Therapeutics
Debt-to-Equity Ratio 11.99 20.99 Crispr Therapeutics
PEG Ratio -9.04 23.07 Crispr Therapeutics
EV/EBITDA -4.80 28.39 Crispr Therapeutics
Profit Margin -215.00% 10.89% Bio-Techne
Operating Margin -17,158.84% 14.10% Bio-Techne
EBITDA Margin N/A 14.10% N/A
Return on Equity -19.71% 6.53% Bio-Techne
Return on Assets -12.88% 5.24% Bio-Techne
Free Cash Flow $-144.68M $236.10M Bio-Techne
Dividend Yield N/A 0.64% N/A
1-Year Return -11.59% -33.33% Crispr Therapeutics
Overview
Performance
Valuation
Financials
Short Interest
Dividends

Crispr Therapeutics vs Bio-Techne Price History Comparison

Key Statistics Comparison

Loading Statistics...

Performance

Crispr Therapeutics vs Bio-Techne Performance Comparison Chart

Loading Price Chart...

Performance Comparison

Loading Performance Data...

Valuation

Valuation History

Loading Valuation History...

Market Capitalization % Change

P/E Ratio (TTM)

Forward P/E

PEG Ratio

Price to Sales (TTM)

Price to Book (MRQ)

Enterprise Value % Change

EV/EBITDA

EV/Revenue

Valuation Metrics

Loading Valuation Metrics...

Financials

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement Comparison (TTM)

Loading Financials...

Short Interest And Ownership

Short Interest And Ownership Metrics

Loading Short Interest And Ownership Data...

Dividends

Dividend Information

Loading Dividend Information...